Citation Tools
PDFRegular and young investigator award abstracts
Combination immunotherapies
442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy